Orexo Q2 2024 Interim Report
Making progress, while the OX124 review time extended Q2 2024 highlights› Total net revenues of SEK 154.0 m (157.7)› EBITDA of SEK 5.0 m (5.6) › Net earnings of SEK -35.9 m (-12.6)› US Commercial segment net revenues of SEK 147.9 m (145.4), in local currency USD 13.9 m (13.8)› Cash flow from operating activities of SEK -6.5 m (-12.7), cash and cash equivalents of SEK 139.7 m (251.1)› Earnings per share before and after dilution amounted to SEK -1.04 (-0.37)› Second patent in the US granted for OX640, a nasal epinephrine powder product › The